Tribunal overturns duty demand, interest, penalties in favor of appellants in brand name dispute

The Tribunal ruled in favor of the appellants, setting aside the duty demand, interest, and penalties imposed by the Commissioner (Appeals). The denial of the SSI exemption was deemed unjustified as multiple manufacturers, including the appellants, used the brand name "Extus." The department failed to prove that the brand names "Colter," "Bezec," and "Fecit C" did not belong to the appellants, leading to the Tribunal allowing the appeal and providing consequential relief as per the law.

---

---

Issues:
Allegation of wrongly availing SSI exemption by using brand names of other persons.

Analysis:
The appellants were accused of wrongly availing the SSI exemption by utilizing brand names belonging to other entities. The case involved the appellants, who are manufacturers of P or P Medicines, being alleged to have used brand names such as "Extus," "Colter," "Bezec," and "Fecit C" in their products, which were claimed to belong to other companies like M/s. Zoetic Formulations and M/s. Care-Med Pharmaceuticals. The adjudicating authority confirmed duty demand, interest, and imposed penalties, which were upheld by the Commissioner (Appeals), leading to this appeal.

The appellants argued that the brand name "Extus" was used by multiple manufacturers, not exclusively owned by any single entity. They presented evidence that other companies like M/s. East West Pharma, M/s. Yashna Drugs, and M/s. Labindus Pharmaceuticals also used the brand name "Extus." The appellants contended that the allegation of using another person's brand name was baseless, especially since M/s. Zoetic Formulations withdrew their application for registration of the brand name. Citing a Supreme Court judgment, the appellants asserted that if multiple entities use the same brand name, the SSI exemption cannot be denied based on such grounds. Regarding the brand names "Colter," "Bezec," and "Fecit C," the appellants argued that there was no evidence to prove these names did not belong to them, with a statement from M/s. Care-Med Pharmaceuticals supporting their claim.

The department, represented by the Ld. AR, reiterated the findings in the impugned order, emphasizing statements from M/s. Care-Med Pharmaceuticals and M/s. Zoetic Formulations claiming ownership of the brand names in question. The department contended that since the appellants failed to provide evidence of ownership of the brand names, they were not eligible for the SSI exemption.

After considering both sides' arguments, the Tribunal found that the brand name "Extus" was used by various manufacturers, as evidenced by documents and a letter from the Drugs Controller. Citing a relevant judgment, the Tribunal held that denial of the SSI exemption based on shared brand names was not justified. Additionally, the department failed to establish that the brand names "Colter," "Bezec," and "Fecit C" did not belong to the appellants, as supported by a statement from M/s. Care-Med Pharmaceuticals. Consequently, the Tribunal set aside the impugned order, allowing the appeal and providing consequential relief as per the law.

In conclusion, the Tribunal ruled in favor of the appellants, finding the denial of SSI exemption unjustified due to the shared use of the brand name "Extus" and the lack of evidence proving that other brand names did not belong to the appellants.

---